HIV Drug Potentially Tied To Liver Damage

Law360, New York (March 13, 2008, 12:00 AM EDT) -- Trying to cover all the bases, the U.S. Food and Drug Administration and a unit of Johnson & Johnson have reportedly joined forces to issue a new warning regarding a potential link between liver damage and the HIV drug Prezista.

On Thursday, a so-called "dear healthcare professional" letter appeared on the FDA Web site from J&J unit Tibotec Therapeutics, alerting the medical community to a spate of liver injuries and deaths connected to the medication.

"Post-marketing cases of liver injury, including some fatalities, have been reported,"...
To view the full article, register now.